Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Down 10.3 %

NASDAQ:EGRX opened at $0.52 on Monday. The stock’s fifty day moving average price is $0.72 and its two-hundred day moving average price is $3.04. Eagle Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $6.81.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC acquired a new position in Eagle Pharmaceuticals during the 2nd quarter valued at about $971,000. Creative Planning bought a new stake in shares of Eagle Pharmaceuticals during the third quarter worth approximately $59,000. Fidelis Capital Partners LLC acquired a new position in Eagle Pharmaceuticals in the second quarter valued at approximately $71,000. Vanguard Personalized Indexing Management LLC bought a new position in Eagle Pharmaceuticals in the second quarter valued at approximately $76,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Eagle Pharmaceuticals in the second quarter valued at approximately $65,000. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.